Pasar al contenido principal

Overcoming Monocarboxylate Transporter 8 (MCT8)-Deficiency on brain development and function

IJC2020-043543-I

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de Promoción del Talento y su Empleabilidad en I+D+i
Subprograma Subprograma Estatal de Incorporación
Convocatoria Juan de la Cierva Incorporación
Año convocatoria 2020
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Intracerebroventricular High Doses of 3,3′,5-Triiodothyroacetic Acid at Juvenile Stages Improve Peripheral Hyperthyroidism and Mediate Thyromimetic Effects in Limited Brain Regions in a Mouse Model of Monocarboxylate Transporter 8 Deficiency

  • Grijota Martínez, María del Carmen
  • Montero-Pedrazuela, Ana
  • Hidalgo-Álvarez, Jorge
  • Bárez-López, Soledad
  • Guadaño-Ferraz, Ana
© Mary Ann Liebert, Inc., [Introduction]: Patients lacking functional monocarboxylate transporter 8 (MCT8), a highly specific thyroid hormone (TH) transporter, present severe psychomotor disabilities. MCT8 deficiency leads to peripheral hyperthyroidism and brain hypothyroidism, the latter due to impaired transport of TH across brain barriers. Available treatments for patients are limited and aim to overcome the limited TH transport across brain barriers. The use of TH analogues such as 3,3′,5-triiodothyroacetic acid (TRIAC) that do not require MCT8 to cross the cellular membranes is considered a potential therapy for MCT8 deficiency. Previous studies have shown that systemic administration of TRIAC at therapeutic doses does not increase TRIAC content in the brain, while intracerebroventricular (ICV) administration of therapeutic doses of TRIAC increases TRIAC content in the brain but does not mediate thyromimetic effects. In view of this, we hypothesize that ICV administration of high doses of TRIAC can mediate thyromimetic effects in the brain without worsening the brain hypothyroidism or peripheral hyperthyroidism of patients. [Methods]: We administered 400 ng/g of body weight per day of ICV TRIAC in a mouse model of MCT8 deficiency: Mct8−/y and deiodinase 2 (Dio2)−/− double knockout mice. The effects of this treatment on TH and TRIAC levels/content in blood and tissues were determined by radioimmunoassay and effects on TH-regulated genes were assessed by real time-quantitative polymerase chain reaction in peripheral and central tissues. [Results]: ICV administration of high doses of TRIAC ameliorated the peripheral hyperthyroidism. In the brain, this treatment did not further aggravate brain hypothyroidism and increased TRIAC content in several brain regions; however, only moderate thyromimetic activity was observed in restricted brain areas. [Conclusion]: Administration of high doses of TRIAC by ICV delivery at juvenile stages in a mouse model of MCT8 deficiency is effective in normalizing peripheral hyperthyroidism but exerts minimal thyromimetic activity in the brain., This research was supported by grants from the Ministerio de Ciencia e Innovacion (MCIN)/AEI/10.13039/501100011033 (Grant No. SAF2017-86342-R to A.G.-F.); MCIN/AEI/10.13039/501100011033/FEDER ‘‘Una manera de hacer Europa’’ (Grant No. PID2020-113139RB-I00 to A.G.-F.); Consejo Superior de Investigaciones Cientı´ficas (Grant No. 2020AEP044 to A.G.-F.); the Sherman Foundation (Grant No. OTR02211 to S.B.-L. and A.G.-F.); Asociacio´n Corriendo con el Corazo´n por Hugo (Grant No. OTR06190 to A.G.-F.); and MCIN/EU (Grant No. IJC2020-043543-I to S.B-L)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Isoflurane Rapidly Modifies Synaptic and Cytoskeletal Phosphoproteomes of the Supraoptic Nucleus of the Hypothalamus and the Cortex

  • Bárez-López, Soledad
  • Gadd, George J.
  • Pauža, Audrys G.
  • Murphy, David
  • Greenwood, Michael P.
© 2023 S. Karger AG, Basel, [Introduction]: Despite the widespread use of general anaesthetics, the mechanisms mediating their effects are still not understood. Although suppressed in most parts of the brain, neuronal activity, as measured by FOS activation, is increased in the hypothalamic supraoptic nucleus (SON) by numerous general anaesthetics, and evidence points to this brain region being involved in the induction of general anaesthesia (GA) and natural sleep. Posttranslational modifications of proteins, including changes in phosphorylation, enable fast modulation of protein function which could be underlying the rapid effects of GA. In order to identify potential phosphorylation events in the brain-mediating GA effects, we have explored the phosphoproteome responses in the rat SON and compared these to cingulate cortex (CC) which displays no FOS activation in response to general anaesthetics., [Methods]: Adult Sprague-Dawley rats were treated with isoflurane for 15 min. Proteins from the CC and SON were extracted and processed for nano-LC mass spectrometry (LC-MS/MS). Phosphoproteomic determinations were performed by LC-MS/MS., [Results]: We found many changes in the phosphoproteomes of both the CC and SON in response to 15 min of isoflurane exposure. Pathway analysis indicated that proteins undergoing phosphorylation adaptations are involved in cytoskeleton remodelling and synaptic signalling events. Importantly, changes in protein phosphorylation appeared to be brain region specific suggesting that differential phosphorylation adaptations might underlie the different neuronal activity responses to GA between the CC and SON., [Conclusion]: In summary, these data suggest that rapid posttranslational modifications in proteins involved in cytoskeleton remodelling and synaptic signalling events might mediate the central mechanisms mediating GA., This research was supported by grants from the Biotechnology and Biological Sciences Research Council (BBSRC; BB/R016879/1) to D.M., S.B-L., and M.P.G., from the Leverhulme Trust (RPG-2017-287) to D.M. and M.P.G., and from the Spanish Ministerio de Ciencia e Innovacion (MCIN/AEI /10.13039/501100011033) and the European Union NextGenerationEU/PRTR (IJC2020-043543-I) to S.B-L. A.G.P. was a recipient of the British Heart Foundation PhD Studentship (BHF FS/17/60/33474)., No
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Defective thyroid hormone transport to the brain leads to astroglial alterations

  • Guillen-Yunta, M.
  • García-Aldea, A.
  • Valcárcel-Hernández, Víctor
  • Sanz-Bógalo, Ainara
  • Muñoz-Moreno, Emma
  • Gisele Matheus, María
  • Grijota Martínez, María del Carmen
  • Montero-Pedrazuela, Ana
  • Guadaño-Ferraz, Ana
  • Bárez-López, Soledad
Allan-Herndon-Dudley syndrome (AHDS) is a rare X-linked disorder that causes severe neurological damage, for which there is no effective treatment. AHDS is due to inactivating mutations in the thyroid hormone transporter MCT8 that impair the entry of thyroid hormones into the brain, resulting in cerebral hypothyroidism. However, the pathophysiology of AHDS is still not fully understood and this is essential to develop therapeutic strategies. Based on evidence suggesting that thyroid hormone deficit leads to alterations in astroglial cells, including gliosis, in this work, we have evaluated astroglial impairments in MCT8 deficiency by means of magnetic resonance imaging, histological, ultrastructural, and immunohistochemical techniques, and by mining available RNA sequencing outputs. Apparent diffusion coefficient (ADC) imaging values obtained from magnetic resonance imaging showed changes indicative of alterations in brain cytoarchitecture in MCT8-deficient patients (n = 11) compared to control subjects (n = 11). Astroglial alterations were confirmed by immunohistochemistry against astroglial markers in autopsy brain samples of an 11-year-old and a 30th gestational week MCT8-deficient subjects in comparison to brain samples from control subjects at similar ages. These findings were validated and further explored in a mouse model of AHDS. Our findings confirm changes in all the astroglial populations of the cerebral cortex in MCT8 deficiency that impact astrocytic metabolic and mitochondrial cellular respiration functions. These impairments arise early in brain development and persist at adult stages, revealing an abnormal distribution, density, morphology of cortical astrocytes, along with altered transcriptome, compatible with an astrogliosis-like phenotype at adult stages. We conclude that astrocytes are potential novel therapeutic targets in AHDS, and we propose ADC imaging as a tool to monitor the progression of neurological impairments and potential effects of treatments in MCT8 deficiency., This study was supported by MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe” (Grants No. SAF2017–86342-R and PID2020-113139RB-I00 to AG-F), Consejo Superior de Investigaciones Científicas (Grant No. 2020AEP044 to AG-F), The Sherman Foundation (Grant No. OTR02211 to SB-L and AG-F), Asociación Corriendo con el Corazón por Hugo (Grant No. OTR06190 to AG-F), a contract from Ministerio de Ciencia, Innovación y Universidades (Programa de Formación de Profesorado (FPU, FPU19/02006) to MG-Y, a contract from Universidad Autónoma de Madrid (Contrato predoctoral para Formación de personal Investigador en Formación, FPI-UAM) to AG-A, a contract from MCIN/AEI/10.13039/501100011033 and “ESF Investing in your future” (Grant No. PRE2018–086185) to VV-H, and a grant from the MCIN/AEI/10.13039/501100011033 and the European Union NextGenerationEU/PRTR (Grant No. IJC2020–043543-I) to SB-L., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Male rat hypothalamic extraretinal photoreceptor Opsin3 is sensitive to osmotic stimuli and light

  • Bárez-López, Soledad
  • Bishop, Paul
  • Searby, Daniel
  • Murphy, David
  • Greenwood, Michael P.
The light-sensitive protein Opsin 3 (Opn3) is present throughout the mammalian brain; however, the role of Opn3 in this organ remains unknown. Since Opn3 encoded mRNA is modulated in the supraoptic and paraventricular nucleus of the hypothalamus in response to osmotic stimuli, we have explored by in situ hybridization the expression of Opn3 in these nuclei. We have demonstrated that Opn3 is present in the male rat magnocellular neurones expressing either the arginine vasopressin or oxytocin neuropeptides and that Opn3 increases in both neuronal types in response to osmotic stimuli, suggesting that Opn3 functions in both cell types and that it might be involved in regulating water balance. Using rat hypothalamic organotypic cultures, we have demonstrated that the hypothalamus is sensitive to light and that the observed light sensitivity is mediated, at least in part, by Opn3. The data suggests that hypothalamic Opn3 can mediate a light-sensitive role to regulate circadian homeostatic processes., This research was supported by grants from the Biotechnology and Biological Sciences Research Council (BBSRC; BB/R016879/1) to David Murphy, Soledad Bárez-López, Paul Bishop and Michael P. Greenwood, from the Leverhulme Trust (RPG-2017-287) to David Murphy and Michael P. Greenwood, from the British Society for Neuroendocrinology (Project Support Grant) to Soledad Bárez-López and from the MCIN/AEI/10.13039/501100011033 and the European Union NextGenerationEU/PRTR (Grant No. IJC2020-043543-I) to Soledad Bárez-López., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Evaluation of the hepatic and subcutaneous adipose tissue effects of triiodothyronine treatment in an animal model of metabolic syndrome

  • Borges-Canha, Marta
  • Leite, Ana Rita
  • Conceição, Glória
  • Vale, Catarina
  • Von-Hafe, Madalena
  • Martín, Diana
  • Miranda-Silva, Daniela
  • Sousa-Mendes, Cláudia
  • Chaves, Joana
  • Lourenço, Inês Mariana
  • Grijota Martínez, María del Carmen
  • Bárez-López, Soledad
  • Miranda, Isabel M.
  • Leite-Moreira, Adelino
  • Falcão-Pires, Inês
  • Neves, João Sérgio
[Background and aims] Metabolic dysfunction associated steatotic liver disease (MASLD) is a metabolic liver disease and thyroid hormones (TH) may decrease liver fat and extra-hepatic fat content. We aimed to evaluate the effects of high and low dose triiodothyronine (T3) in liver and subcutaneous adipose tissue (sAT) in an animal model of Metabolic Syndrome (MS)., [Methods and results] Four groups were evaluated: 1) ZSF1 Lean (Lean-Ctrl, n = 8); 2) ZSF1 obese (rat model of MS with MASLD, MetS, n = 13); 3) ZSF1 obese supplemented with high-dose of T3 (MetS-hT3, n = 5); and 4) ZSF1 obese supplemented with a low-dose of T3 (MetS-lT3, n = 8). Treatment with both doses of T3 decreased body weight, liver weight and perirenal fat. High-dose T3 treatment normalized the increased expression of COL3A1 in MetS group. Histologically, lipid hepatic burden in treated groups was significantly reduced. Adipocytes and adipocytes’ fibrosis areas were significantly reduced by the treatment with T3. MetS-hT3 had an increased risk of arrhythmias and sudden death., [Conclusion] Treatment with T3 improves steatosis and fibrosis at the liver and sAT in animals with MS. High doses of T3 may not be safe due to the risk of cardiac events. Our results support new therapeutic strategies for MASLD focused on the modulation of TH., This study was funded by national funds through FCT - Portuguese Foundation for Science and Technology, under the scope of the Cardiovascular R&D Center – UnIC (UIDB/00051/2020 and UIDP/00051/2020). Soledad Bárez-López: European Union NextGenerationEU/PRTR (Grant No. IJC2020–043543-I)., Peer reviewed